4-AcO-DMT

Closure of psx:substance/4-aco-dmt/section/safety.full@1: 44 upstream, 17 downstream.

psx:substance/4-aco-dmt/section/safety.full@1
├─ informed_by  claim/5adcc309-1144-4739-93f0-49abbf43c177  Claim in safety — supported
├─ informed_by  claim/c626184b-f24c-4fd4-ab58-e31874e88845  Claim in safety — inconclusive  working
├─ informed_by  claim/6cddc844-8d72-4c45-83a5-abf4d8bfd458  Claim in safety — supported
├─ informed_by  claim/f283917e-d2bc-48b6-96ea-93f5272cabb6  Claim in safety — inconclusive  working
├─ informed_by  claim/98aafcb6-7ddc-4faa-b4c7-5cd180683323  Claim in safety — partially_supported
├─ informed_by  claim/ff3f3dfc-0129-4863-8282-c15d5e46c69c  Claim in safety — inconclusive  working
├─ informed_by  claim/b94dc1de-29e5-4570-8290-80ccfc41ccea  Claim in safety — supported
├─ informed_by  claim/2d58d95d-b4d6-4837-a2a2-bd7d4c2caed4  Claim in safety — inconclusive  working
├─ informed_by  claim/166872ec-86ef-471d-ba5d-44f41f7855b8  Claim in safety — inconclusive  working
├─ informed_by  claim/44d7bb43-e7a6-487e-9798-522b526059c4  Claim in safety — supported
├─ informed_by  claim/1d679b3b-9329-4d92-a2c3-eeb3c6d360e1  Claim in safety — inconclusive  working
├─ informed_by  claim/0fe71528-28d1-4e93-95bd-0c35037c9568  Claim in safety — inconclusive  working
├─ informed_by  claim/36ce5222-048e-4736-af2c-503cda399548  Claim in safety — inconclusive  working
├─ informed_by  claim/26c584ca-5ec7-49d9-9985-99a234914111  Claim in safety — inconclusive  working
├─ informed_by  claim/504f08c2-e559-403a-86b8-e8fd85940862  Claim in safety — inconclusive  working
├─ informed_by  claim/a5ee8056-ef18-4f6d-b46f-8838920c895f  Claim in safety — not_supported  working
  ├─ used  src/doi:10.1007/s00204-026-04365-4  In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin
  ├─ used  src/doi:10.3390/brainsci8030047  Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
  ├─ used  src/doi:10.3389/fphar.2017.00423  A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
  ├─ used  src/doi:10.1016/j.celrep.2023.112203  A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
  ├─ used  src/doi:10.1007/7854_2017_475  Chemistry and Structure-Activity Relationships of Psychedelics.
  ├─ used  src/doi:10.1016/j.neulet.2023.137597  Rewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process Theory
  ├─ used  src/pmid:16051647  Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
  ├─ used  src/doi:10.1007/s40263-025-01256-7  Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
  ├─ used  src/doi:10.1007/s00204-024-03952-7  Elucidating the Phase I metabolism of psilocin in vitro
  ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
      ├─ used  src/doi:10.1021/acsptsci.2c00177  Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
      ├─ used  src/doi:10.1002/dta.3255  Tentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS
      ├─ used  src/doi:10.1055/s-1999-3490  Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin
      ├─ used  src/doi:10.1021/acsptsci.2c00222  Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
      ├─ used  src/url:7a90964f24ed4f5d  4-AcO-DMT (Psilacetin) - Erowid Basics
      ├─ used  src/url:946c31199207c835  4-AcO-DMT
      ├─ used  src/doi:10.1107/s2056989019007370  Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug
      ├─ used  src/doi:10.3389/fpsyt.2023.1303365  In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
      ├─ used  src/doi:10.1111/1556-4029.15167  Psilocin - The 'real deal' or an extraction byproduct
      ├─ used  src/doi:10.1016/j.cell.2020.08.024  Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
      ├─ used  src/doi:10.3390/pharmaceutics17040411  Pharmacokinetics of Psilocybin: A Systematic Review
      ├─ used  src/doi:10.1007/s40262-024-01454-4  Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
      ├─ used  src/doi:10.1016/j.neuron.2025.06.012  The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
      ├─ used  src/doi:10.1111/bph.70307  5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation
      ├─ used  src/doi:10.1016/j.euroneuro.2016.05.001  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
      ├─ used  src/doi:10.3390/life13122345  Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue
      ├─ used  src/doi:10.3390/cimb45080427  Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
      └─ generated_by  pub/9aa9e7e9-e7aa-40c4-b484-d5fa3248e35f  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/8ce5caf4-3bd0-4038-b8be-31f2ef1c2ee1  Claim in summary — supported
    ├─ used  claim/550e91ac-8658-40b3-8428-aebc20c8ca9f  Claim in pharmacology — inconclusive  working
    ├─ used  claim/f894156e-b5ac-4d13-958d-46d48eceeb4c  Claim in chemistry — inconclusive  working
    ├─ used  claim/3d1e478c-9501-4f1f-b62a-5720a25da6e0  Claim in summary — supported
    ├─ used  claim/017d8a68-0053-48fc-939e-7c5a7b596853  Claim in pharmacology — supported
    ├─ used  claim/3010606d-ab9b-461d-9cd2-d42aae4d1132  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ derived_from  issue/notice@b90cab31cadf  Issued notice
      ├─ derived_from  issue/info_card@2b6c0a7b280e  Issued info_card
      ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
      ├─ derived_from  issue/notice@9a96b1160ba9  Issued notice
      ├─ derived_from  issue/info_card@017f70fc6826  Issued info_card
      ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/pharmacology.full@1
      ├─ informed_by  section/chemistry.full@1
      └─ informed_by  section/pharmacokinetic-detail.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage